
LifeMD (LFMD) Stock Forecast & Price Target
LifeMD (LFMD) Analyst Ratings
Bulls say
LifeMD is a telehealth and digital health company with potential growth and risks from competition, lower than expected growth, patient acquisition difficulties, and dilution. Management has some confidence in the future growth prospects as they plan to expand its primary care capabilities and form partnerships, along with investing in AI and launching insurance services. Their strong financial performance and potential partnerships, along with providing competitive prices for GLP-1 medications, give LifeMD a Buy rating with a $10 price target.
Bears say
LifeMD is heavily reliant on its direct-to-patient marketing infrastructure and subscription-based model, which is vulnerable to changes in government regulations and reimbursement rates. The company has a significant cash burn rate and relies on continued investors to stay afloat, putting pressure on future profitability. Additionally, with a young and competitive telehealth industry, there is uncertainty around LifeMD's ability to maintain its current market position and sustain long-term growth.
This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.
LifeMD (LFMD) Analyst Forecast & Price Prediction
Start investing in LifeMD (LFMD)
Order type
Buy in
Order amount
Est. shares
0 shares